Insulin Delivery
Are better insulins still needed?

Many people with type 2 diabetes are only on a basal insulin and are more dependent on noninsulin therapies, and with the advent of additional noninsulin options, such as GLP-1 receptor agonists or SGLT2 inhibitors, their outcomes are improving. There is a community out there that feels that insulins are as good as they can be.
Insulet announces partnerships with Abbott, Dexcom for its tubeless artificial pancreas system
Medtronic recalls some MiniMed insulin pumps for incorrect dosing
Insulin aspart biosimilar safe for pump therapy use in type 1 diabetes

A follow-on therapy to insulin aspart was shown to be safe and effective for pump use among adults with type 1 diabetes, with no increased incidence of unexplained hypoglycemia when compared with the reference product, according to findings from an open-label crossover study published in Diabetes Technology & Therapeutics.
Mobile closed-loop insulin system bests sensor-augmented pump in preventing hypoglycemia
FDA approves rapid-acting insulin for children with diabetes
Top diabetes device news of 2019: ‘digiceuticals,’ interoperable devices, insurance coverage and more
High discontinuation rate for artificial pancreas among youths with type 1 diabetes

Approximately half of children and young adults with type 1 diabetes who initiated use of a hybrid closed-loop insulin delivery system, also known as an artificial pancreas, were still using the device in auto mode after 6 months, with 30% of youths discontinuing use of the system altogether, according to findings from a real-world study published in Pediatric Diabetes.
Bionic pancreas receives FDA breakthrough device designation
Noninjectable options to deliver insulin, manage diabetes

LOS ANGELES — Several cutting-edge advances in noninjectable insulin delivery methods could offer new ways for people with diabetes to manage the disease and better control glucose response, with the possibility of an oral insulin formulation closer than ever before to becoming reality, according to a speaker at the World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease.